Geron publishes results from IMerge trial in The Lancet

Geron announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes, or MDS, relapsed/refractory or ineligible for erythropoiesis stimulating agents, or ESAs. The publication is available online and will be available in print at a later date. Imetelstat is currently under regulatory review by the FDA and by the European Medicines Agency, or EMA. for approval in transfusion dependent anemia in patients with lower risk MDS who have failed to respond or have lost response to or are ineligible for ESAs.